Blood markers for ferroptosis in Alopecia Areata
Part of Skin clinical trials.
This study looks at certain blood markers (GPX4 and MDA) related to a process called ferroptosis in people with Alopecia Areata. The goal is to better understand this condition and possibly find new treatment targets.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been formally diagnosed with Alopecia Areata by a doctor.
- You have not used steroid creams or injections on your scalp in the last month.
- You have not taken strong oral immune-suppressing medications in the last 3 months.
- You do not have other active autoimmune or inflammatory skin conditions.
- You are not pregnant, breastfeeding, or a heavy smoker, and you have not taken high-dose antioxidant supplements regularly.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether certain proteins in your blood (VEGF-A and VCAM-1) are linked to changes in the tiny blood vessels at the base of your fingernails in people with alopecia areata. It may help doctors understand more about the condition and how it affects the body.
This study tests an investigational drug to see if it can help people with severe alopecia areata, a condition that causes hair loss. It may help regrow hair.
This study tests whether transplanting healthy gut bacteria (called a fecal microbiota transplant) can help treat alopecia areata, a condition that causes patchy hair loss. By restoring a balanced gut microbiome, the treatment may reduce inflammation and potentially promote hair regrowth.
This trial tests a new drug called FB102 for people with severe to very severe alopecia areata, a condition that causes at least half of scalp hair to be lost. It aims to see if the drug is safe and can help hair grow back.
This trial tests a new drug, HCW9302, that targets the immune system to help hair regrow in people with alopecia areata (including extensive forms like totalis or universalis). It may be an option for adults who have not responded well to other treatments.
This study tracks the safety and effectiveness of alopecia areata treatments in teenagers aged 12-17. It helps doctors understand which treatments work best and are safest for young people with severe hair loss.
Hear when a new Alopecia Areata trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.